Study to Compare Feasibility of 1-step Injectable Artesunate vs. Conventional 2-step Injectable Artesunate (1STEP-AS)
Convenience and Cost-aspects of a New 1-step Reconstitution Injectable Artesunate Compared to Conventional 2-step Injectable Artesunate for the Treatment of Severe Falciparum Malaria: a Multi-centre Study
Sponsor: National Institute for Medical Research, Tanzania
This PHASE2 trial investigates Severe Malaria and is currently completed. National Institute for Medical Research, Tanzania leads this study, which shows 10 recorded versions since 2022 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Apr 2024 — Jul 2024 [monthly]
Completed PHASE2
-
Nov 2023 — Apr 2024 [monthly]
Completed PHASE2
Status: Recruiting → Completed
▶ Show 5 earlier versions
-
Sep 2022 — Nov 2023 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jul 2022 — Sep 2022 [monthly]
Not Yet Recruiting PHASE2
-
May 2022 — Jul 2022 [monthly]
Not Yet Recruiting PHASE2
-
Apr 2022 — May 2022 [monthly]
Not Yet Recruiting PHASE2
-
Jan 2022 — Apr 2022 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute for Medical Research, Tanzania
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
- University of Kinshasa
- University of Oxford
For direct contact, visit the study record on ClinicalTrials.gov .